Matthew Harrison
Stock Analyst at Morgan Stanley
(3.56)
# 945
Out of 4,479 analysts
507
Total ratings
49.02%
Success rate
4.27%
Average return
Main Sectors:
62 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $165 → $200 | $154.20 | +29.70% | 28 | Jun 24, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $8.77 | +25.43% | 9 | Jun 21, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Equal-Weight | $38 → $8 | $3.57 | +124.09% | 4 | Jun 18, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $515 → $510 | $435.49 | +17.11% | 13 | May 28, 2024 | |
| INSM Insmed | Maintains: Overweight | $40 → $43 | $64.50 | -33.33% | 8 | May 10, 2024 | |
| EDIT Editas Medicine | Upgrades: Equal-Weight | $7 | $4.54 | +54.19% | 11 | May 9, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $80 → $78 | $68.40 | +14.04% | 24 | Apr 26, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $112 | $82.22 | +36.22% | 17 | Apr 26, 2024 | |
| PHVS Pharvaris | Maintains: Overweight | $34 | $16.85 | +101.78% | 14 | Apr 22, 2024 | |
| GMAB Genmab | Maintains: Underweight | $32 | $24.90 | +28.51% | 20 | Mar 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,104 → $1,115 | $1,044.66 | +6.73% | 29 | Mar 13, 2024 | |
| BIIB Biogen | Maintains: Overweight | $361 → $373 | $228.82 | +63.01% | 32 | Nov 10, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $359 → $364 | $473.78 | -23.17% | 14 | Nov 8, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Overweight | $42 → $38 | $41.23 | -7.83% | 6 | Nov 2, 2023 | |
| BGNE BeiGene | Maintains: Overweight | $321 → $319 | $143.93 | +121.64% | 14 | Aug 29, 2023 | |
| IOBT IO Biotech | Maintains: Overweight | $11 → $7 | $1.18 | +493.22% | 3 | Aug 15, 2023 | |
| PRME Prime Medicine | Maintains: Equal-Weight | $21 → $19 | $5.28 | +259.85% | 3 | Aug 14, 2023 | |
| TNYA Tenaya Therapeutics | Maintains: Overweight | $13 → $14 | $2.98 | +370.59% | 4 | Aug 10, 2023 | |
| ALEC Alector | Reiterates: Equal-Weight | $10 | $4.34 | +130.41% | 6 | Aug 7, 2023 | |
| MRNA Moderna | Maintains: Equal-Weight | $128 → $123 | $117.07 | +5.07% | 19 | Aug 4, 2023 | |
| TSVT 2seventy bio | Downgrades: Equal-Weight | $25 → $13 | $3.86 | +236.79% | 8 | Jul 28, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $85 | $44.74 | +89.99% | 8 | Jul 20, 2023 | |
| BLUE bluebird bio | Reiterates: Underweight | $3 | $0.92 | +224.99% | 17 | Jul 11, 2023 | |
| CMCSA Comcast | Reiterates: Buy | $46 | $38.16 | +20.55% | 1 | Apr 24, 2023 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $61 → $63 | $21.74 | +189.79% | 8 | Apr 12, 2023 | |
| VIGL Vigil Neuroscience | Maintains: Equal-Weight | $12 → $13 | $4.01 | +224.59% | 4 | Mar 27, 2023 | |
| IVVD Invivyd | Maintains: Underweight | $2 → $1 | $1.10 | -9.09% | 3 | Mar 27, 2023 | |
| INVA Innoviva | Maintains: Underweight | $13 → $10 | $16.50 | -39.39% | 8 | Mar 3, 2023 | |
| FULC Fulcrum Therapeutics | Downgrades: Equal-Weight | $27 → $8 | $6.10 | +31.15% | 8 | Feb 28, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $57 → $44 | $25.34 | +73.64% | 16 | Feb 27, 2023 | |
| SANA Sana Biotechnology | Maintains: Overweight | $15 → $13 | $5.35 | +142.99% | 3 | Jan 24, 2023 | |
| LYEL Lyell Immunopharma | Maintains: Equal-Weight | $7 → $4 | $1.51 | +164.90% | 4 | Jan 24, 2023 | |
| BOLT Bolt Biotherapeutics | Maintains: Equal-Weight | $5 → $3 | $0.74 | +308.16% | 4 | Jan 24, 2023 | |
| BNTX BioNTech SE | Maintains: Equal-Weight | $203 → $216 | $78.76 | +174.25% | 8 | Jan 24, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Underweight | $7 → $4 | $3.23 | +23.84% | 7 | Jan 24, 2023 | |
| ADCT ADC Therapeutics | Maintains: Equal-Weight | $7 → $5 | $3.48 | +43.68% | 8 | Jan 24, 2023 | |
| ADAG Adagene | Maintains: Overweight | $7 → $5 | $2.99 | +67.22% | 6 | Jan 24, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $178 → $182 | $165.96 | +9.66% | 7 | Dec 6, 2022 | |
| KOD Kodiak Sciences | Maintains: Equal-Weight | $12 → $9 | $2.24 | +301.79% | 9 | Nov 14, 2022 | |
| AKRO Akero Therapeutics | Maintains: Equal-Weight | $30 → $40 | $22.38 | +78.73% | 5 | Nov 7, 2022 | |
| AMGN Amgen | Maintains: Overweight | $279 → $282 | $310.77 | -9.26% | 20 | Nov 4, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $220 → $210 | $247.61 | -15.19% | 7 | Oct 28, 2022 | |
| ALVR AlloVir | Maintains: Overweight | $32 → $27 | $0.74 | +3,573.47% | 5 | Sep 9, 2022 | |
| PFE Pfizer | Maintains: Equal-Weight | $55 → $52 | $27.83 | +86.85% | 5 | May 4, 2022 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $175 → $173 | $146.03 | +18.47% | 3 | Apr 6, 2022 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $61 → $57 | $10.82 | +426.80% | 4 | Mar 10, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $156 → $120 | $40.96 | +192.97% | 5 | Feb 1, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $145 → $148 | $34.17 | +333.13% | 9 | Jan 7, 2022 | |
| MRK Merck & Co. | Maintains: Equal-Weight | n/a | $127.72 | - | 4 | Nov 29, 2021 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | n/a | $40.45 | - | 2 | Oct 12, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | n/a | $2.16 | - | 2 | Aug 18, 2021 | |
| RPRX Royalty Pharma | Maintains: Equal-Weight | n/a | $25.88 | - | 1 | Aug 16, 2021 | |
| OGN Organon & Co. | Maintains: Equal-Weight | n/a | $20.12 | - | 1 | Aug 16, 2021 | |
| LLY Eli Lilly | Maintains: Overweight | n/a | $906.71 | - | 1 | Aug 4, 2021 | |
| TV Grupo Televisa, S.A.B. | Initiates: Buy | n/a | $2.62 | - | 1 | Jun 24, 2021 | |
| RGNX REGENXBIO | Maintains: Overweight | n/a | $10.75 | - | 4 | Mar 8, 2021 | |
| HBAN Huntington Bancshares | Maintains: Equal-Weight | n/a | $13.21 | - | 1 | Feb 24, 2021 | |
| UBX Unity Biotechnology | Downgrades: Equal-Weight | n/a | $1.31 | - | 2 | Aug 18, 2020 | |
| EVLO Evelo Biosciences | Downgrades: Equal-Weight | n/a | $0.04 | - | 1 | May 21, 2020 | |
| INCY Incyte | Maintains: Equal-Weight | n/a | $59.02 | - | 1 | Jan 6, 2020 | |
| RDUS Radius Health | Maintains: Overweight | n/a | $14.67 | - | 4 | Oct 11, 2018 | |
| CYTK Cytokinetics | Assumes: Equal-Weight | n/a | $54.84 | - | 4 | Sep 10, 2018 |
Sarepta Therapeutics
Jun 24, 2024
Maintains: Overweight
Price Target: $165 → $200
Current: $154.20
Upside: +29.70%
Centessa Pharmaceuticals
Jun 21, 2024
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.77
Upside: +25.43%
Zentalis Pharmaceuticals
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $38 → $8
Current: $3.57
Upside: +124.09%
argenx SE
May 28, 2024
Maintains: Overweight
Price Target: $515 → $510
Current: $435.49
Upside: +17.11%
Insmed
May 10, 2024
Maintains: Overweight
Price Target: $40 → $43
Current: $64.50
Upside: -33.33%
Editas Medicine
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $4.54
Upside: +54.19%
Gilead Sciences
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $80 → $78
Current: $68.40
Upside: +14.04%
BioMarin Pharmaceutical
Apr 26, 2024
Maintains: Overweight
Price Target: $115 → $112
Current: $82.22
Upside: +36.22%
Pharvaris
Apr 22, 2024
Maintains: Overweight
Price Target: $34
Current: $16.85
Upside: +101.78%
Genmab
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $24.90
Upside: +28.51%
Regeneron Pharmaceuticals
Mar 13, 2024
Maintains: Overweight
Price Target: $1,104 → $1,115
Current: $1,044.66
Upside: +6.73%
Biogen
Nov 10, 2023
Maintains: Overweight
Price Target: $361 → $373
Current: $228.82
Upside: +63.01%
Vertex Pharmaceuticals
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $359 → $364
Current: $473.78
Upside: -23.17%
Cerevel Therapeutics Holdings
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $41.23
Upside: -7.83%
BeiGene
Aug 29, 2023
Maintains: Overweight
Price Target: $321 → $319
Current: $143.93
Upside: +121.64%
IO Biotech
Aug 15, 2023
Maintains: Overweight
Price Target: $11 → $7
Current: $1.18
Upside: +493.22%
Prime Medicine
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $5.28
Upside: +259.85%
Tenaya Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $13 → $14
Current: $2.98
Upside: +370.59%
Alector
Aug 7, 2023
Reiterates: Equal-Weight
Price Target: $10
Current: $4.34
Upside: +130.41%
Moderna
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $128 → $123
Current: $117.07
Upside: +5.07%
2seventy bio
Jul 28, 2023
Downgrades: Equal-Weight
Price Target: $25 → $13
Current: $3.86
Upside: +236.79%
Legend Biotech
Jul 20, 2023
Maintains: Overweight
Price Target: $65 → $85
Current: $44.74
Upside: +89.99%
bluebird bio
Jul 11, 2023
Reiterates: Underweight
Price Target: $3
Current: $0.92
Upside: +224.99%
Comcast
Apr 24, 2023
Reiterates: Buy
Price Target: $46
Current: $38.16
Upside: +20.55%
Denali Therapeutics
Apr 12, 2023
Maintains: Overweight
Price Target: $61 → $63
Current: $21.74
Upside: +189.79%
Vigil Neuroscience
Mar 27, 2023
Maintains: Equal-Weight
Price Target: $12 → $13
Current: $4.01
Upside: +224.59%
Invivyd
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.10
Upside: -9.09%
Innoviva
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $16.50
Upside: -39.39%
Fulcrum Therapeutics
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $6.10
Upside: +31.15%
Galapagos NV
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $25.34
Upside: +73.64%
Sana Biotechnology
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $5.35
Upside: +142.99%
Lyell Immunopharma
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $4
Current: $1.51
Upside: +164.90%
Bolt Biotherapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $0.74
Upside: +308.16%
BioNTech SE
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $78.76
Upside: +174.25%
Atea Pharmaceuticals
Jan 24, 2023
Maintains: Underweight
Price Target: $7 → $4
Current: $3.23
Upside: +23.84%
ADC Therapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.48
Upside: +43.68%
Adagene
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $2.99
Upside: +67.22%
AbbVie
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $165.96
Upside: +9.66%
Kodiak Sciences
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $2.24
Upside: +301.79%
Akero Therapeutics
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $30 → $40
Current: $22.38
Upside: +78.73%
Amgen
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $310.77
Upside: -9.26%
Alnylam Pharmaceuticals
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $247.61
Upside: -15.19%
AlloVir
Sep 9, 2022
Maintains: Overweight
Price Target: $32 → $27
Current: $0.74
Upside: +3,573.47%
Pfizer
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $27.83
Upside: +86.85%
Johnson & Johnson
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $146.03
Upside: +18.47%
Sage Therapeutics
Mar 10, 2022
Maintains: Equal-Weight
Price Target: $61 → $57
Current: $10.82
Upside: +426.80%
Ultragenyx Pharmaceutical
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $40.96
Upside: +192.97%
Biohaven Pharmaceutical Holding Company
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $34.17
Upside: +333.13%
Merck & Co.
Nov 29, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $127.72
Upside: -
Bristol-Myers Squibb Company
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $40.45
Upside: -
Taysha Gene Therapies
Aug 18, 2021
Maintains: Overweight
Price Target: n/a
Current: $2.16
Upside: -
Royalty Pharma
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $25.88
Upside: -
Organon & Co.
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $20.12
Upside: -
Eli Lilly
Aug 4, 2021
Maintains: Overweight
Price Target: n/a
Current: $906.71
Upside: -
Grupo Televisa, S.A.B.
Jun 24, 2021
Initiates: Buy
Price Target: n/a
Current: $2.62
Upside: -
REGENXBIO
Mar 8, 2021
Maintains: Overweight
Price Target: n/a
Current: $10.75
Upside: -
Huntington Bancshares
Feb 24, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $13.21
Upside: -
Unity Biotechnology
Aug 18, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $1.31
Upside: -
Evelo Biosciences
May 21, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $0.04
Upside: -
Incyte
Jan 6, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $59.02
Upside: -
Radius Health
Oct 11, 2018
Maintains: Overweight
Price Target: n/a
Current: $14.67
Upside: -
Cytokinetics
Sep 10, 2018
Assumes: Equal-Weight
Price Target: n/a
Current: $54.84
Upside: -